BR112018000660A2 - peptídeos anti-inflamatórios e seu uso - Google Patents

peptídeos anti-inflamatórios e seu uso

Info

Publication number
BR112018000660A2
BR112018000660A2 BR112018000660-2A BR112018000660A BR112018000660A2 BR 112018000660 A2 BR112018000660 A2 BR 112018000660A2 BR 112018000660 A BR112018000660 A BR 112018000660A BR 112018000660 A2 BR112018000660 A2 BR 112018000660A2
Authority
BR
Brazil
Prior art keywords
antiinflammatory
region
fragment
amino acid
methionine
Prior art date
Application number
BR112018000660-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Khaldi Nora
Lopez Cyril
Adlefio Alessandro
Original Assignee
Nuritas Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15177013.8A external-priority patent/EP3118215A1/en
Priority claimed from EP15177017.9A external-priority patent/EP3118216A1/en
Application filed by Nuritas Limited filed Critical Nuritas Limited
Publication of BR112018000660A2 publication Critical patent/BR112018000660A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
BR112018000660-2A 2015-07-16 2016-07-18 peptídeos anti-inflamatórios e seu uso BR112018000660A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15177013.8 2015-07-16
EP15177013.8A EP3118215A1 (en) 2015-07-16 2015-07-16 Anti-inflammatory peptides, and uses thereof
EP15177017.9A EP3118216A1 (en) 2015-07-16 2015-07-16 Cellular growth and proliferation promoting peptides, and uses thereof
EP15177017.9 2015-07-16
PCT/EP2016/067090 WO2017009484A1 (en) 2015-07-16 2016-07-18 Anti-inflammatory peptides, and uses thereof

Publications (1)

Publication Number Publication Date
BR112018000660A2 true BR112018000660A2 (pt) 2019-05-14

Family

ID=56686757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000660-2A BR112018000660A2 (pt) 2015-07-16 2016-07-18 peptídeos anti-inflamatórios e seu uso

Country Status (12)

Country Link
US (4) US10463591B2 (https=)
EP (3) EP3954700A1 (https=)
JP (3) JP2018523703A (https=)
KR (3) KR20230132623A (https=)
CN (2) CN114835784B (https=)
AU (2) AU2016293129B2 (https=)
BR (1) BR112018000660A2 (https=)
CA (1) CA2992378A1 (https=)
DK (1) DK3322430T3 (https=)
ES (1) ES2806989T3 (https=)
MX (2) MX377692B (https=)
WO (1) WO2017009484A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932498T3 (es) * 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
JP7340314B2 (ja) * 2020-01-15 2023-09-07 Tdk株式会社 米に含まれるタンパク質の含有量を測定する方法
KR102354916B1 (ko) * 2020-02-11 2022-01-26 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도
FR3114744B1 (fr) 2020-10-02 2024-01-05 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer le confort de la peau et/ou des muqueuses et/ou l’apparence des phanères
EP4265630A4 (en) * 2020-12-16 2024-12-11 Ajou University Industry-Academic Cooperation Foundation ANTI-INFLAMMATORY PEPTIDE TO PREVENT OR TREAT ATOPIC DERMATITIS
CN114478702B (zh) * 2022-04-06 2023-12-12 中南林业科技大学 一种米糠来源短肽及其在治疗皮肤损伤中的应用
CN116375828B (zh) * 2022-09-08 2024-06-04 浙江大学 一种具有抗菌活性的抗菌肽kta及其应用
CN116253782B (zh) * 2022-09-08 2024-06-04 浙江大学 一种广谱抗菌肽ktr及其应用
CN116589528A (zh) * 2022-09-21 2023-08-15 江阴天江药业有限公司 一种广地龙特征肽及其应用
FR3141066B1 (fr) * 2022-10-24 2026-04-10 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer la matrice extracellulaire du derme de la peau et/ou des muqueuses
CN116491631B (zh) * 2023-05-26 2024-06-25 青岛农业大学 一种预制菜红烧肉及其制备方法
WO2024259556A1 (en) * 2023-06-19 2024-12-26 Viage Therapeutics, Inc. Uses of therapeutic peptides
CN117736271B (zh) * 2023-06-29 2024-08-09 长沙理工大学 一种米渣蛋白源免疫活性肽及其应用
WO2025133189A1 (en) * 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
EP4666996A1 (en) * 2024-06-21 2025-12-24 Quiris Healthcare GmbH & Co. KG Composition containing peptides of vegetable origin
CN120574921B (zh) * 2025-08-06 2026-02-06 浙江诺衍生物科技有限公司 一种有助于降血糖的大米肽及其应用
CN120590476A (zh) * 2025-08-06 2025-09-05 浙江诺衍生物科技有限公司 一种有助于降血糖的七肽及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5520935A (en) 1991-03-07 1996-05-28 Novo Nordisk A/S Method for production of pea protein hydrolyzate
US5516642A (en) 1992-11-16 1996-05-14 Bristol-Myers Squibb Company Polypeptides derived from major histocompatibility complex Class I antigen
JP2673659B2 (ja) 1994-02-11 1997-11-05 株式会社ホーネンコーポレーション ペプチド
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
IT1313572B1 (it) 1999-07-27 2002-09-09 Enichem Spa Procedimento per la preparazione di epossidi.
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP2001335596A (ja) 2000-05-24 2001-12-04 Kenji Sakamoto 新規ペプチド及びその医薬用途
AR035860A1 (es) 2001-04-17 2004-07-21 Femtolink Biotechnologies Llc Metodos de deteccion por espectrometria de masa y cuantificacion de proteinas blanco especificas en muestras biologicas complejas
AU2003290582A1 (en) 2002-11-04 2004-06-07 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
WO2005023290A2 (en) 2003-05-23 2005-03-17 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
JP4256389B2 (ja) 2003-11-17 2009-04-22 セダーマ テトラペプチドとトリペプチドの混合物を含む組成物
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US8575307B2 (en) 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
KR100759495B1 (ko) 2006-02-17 2007-09-18 재단법인서울대학교산학협력재단 친수성 생리활성 펩타이드와 소수성 물질을 포함한자기조립 나노구조체
US8343531B2 (en) 2006-04-21 2013-01-01 Meiji Co., Ltd. Composition containing peptide as active ingredient
US9034402B2 (en) 2007-04-16 2015-05-19 Solae, Llc Protein hydrolysate compositions having improved sensory characteristics and physical properties
US20110214199A1 (en) 2007-06-06 2011-09-01 Monsanto Technology Llc Genes and uses for plant enhancement
CA2697413A1 (en) * 2007-08-24 2009-03-05 Mylexa Pty Limited Modulators of hypersensitivity reactions
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
WO2011007612A1 (ja) * 2009-07-13 2011-01-20 不二製油株式会社 経口性抗炎症剤及び経口性抗炎症ペプチド
WO2011122937A1 (en) 2010-03-29 2011-10-06 N.V. Nutricia Pea protein peptides with anti helicobacter pylori activity
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
WO2013092851A1 (en) * 2011-12-21 2013-06-27 Laboratorios Ordesa, S.L. Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
CN105163748B (zh) * 2013-02-19 2017-11-21 达能股份公司 用于肥胖症的功能性多肽
CN105708748B (zh) 2014-12-04 2020-06-30 玫琳凯有限公司 化妆品组合物
US20170183386A1 (en) 2015-07-16 2017-06-29 Nuritas Limited Peptides, and uses thereof

Also Published As

Publication number Publication date
DK3322430T3 (da) 2020-06-29
EP3747425A1 (en) 2020-12-09
EP3322430A1 (en) 2018-05-23
EP3954700A1 (en) 2022-02-16
CN114835784B (zh) 2025-06-13
US10463591B2 (en) 2019-11-05
JP7739355B2 (ja) 2025-09-16
KR20180029237A (ko) 2018-03-20
AU2016293129B2 (en) 2021-01-28
JP7288026B2 (ja) 2023-06-06
US11779531B2 (en) 2023-10-10
US20190029939A1 (en) 2019-01-31
CN114835784A (zh) 2022-08-02
CN108348568B (zh) 2021-12-28
AU2016293129A1 (en) 2018-02-01
KR20230132623A (ko) 2023-09-15
MX377692B (es) 2025-03-10
ES2806989T3 (es) 2021-02-19
CA2992378A1 (en) 2017-01-19
EP3322430B1 (en) 2020-03-25
CN108348568A (zh) 2018-07-31
US20240238184A1 (en) 2024-07-18
AU2021202423A1 (en) 2021-05-13
KR102576571B1 (ko) 2023-09-11
MX2018000697A (es) 2018-08-15
US20220233425A1 (en) 2022-07-28
KR102307260B1 (ko) 2021-10-01
JP2022009415A (ja) 2022-01-14
US20200060956A1 (en) 2020-02-27
JP2018523703A (ja) 2018-08-23
JP2023109950A (ja) 2023-08-08
KR20210120134A (ko) 2021-10-06
WO2017009484A1 (en) 2017-01-19
MX2020010806A (es) 2020-10-28
US11253456B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
PE20181923A1 (es) Neoantigenos y metodos de su uso
EA201691111A1 (ru) Химерные белки фактора viii и их применение
EA201390820A1 (ru) Слитый белок против рака
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
EA201491049A1 (ru) Противораковый слитый белок
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
JP2017512063A5 (https=)
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
EA201491277A1 (ru) Противораковый слитый белок
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements